Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Hemostemix Inc V.HEM

Alternate Symbol(s):  HMTXF

Hemostemix Inc. is a Canada-based clinical-stage biotechnology company. The Company’s principal business is to develop, manufacture and commercialize blood-derived stem cell therapies to treat various diseases. It is an autologous stem cell therapeutics company that holds 91 patents on the derivation of three stem cell lineages from the patient’s blood, including angiogenic cell precursors (ACP-01), neuronal cell precursors, and cardiomyocyte cell precursors. ACP-01 is a lead clinical-stage candidate, like NCP-01 and CCP-01, is generated from the patient’s blood. The Company is engaged in providing treatment for ischemia, such as ischemic cardiomyopathy, angina, peripheral arterial disease including critical limb ischemia. The Company’s proprietary technology is a personalized regenerative therapy that is administered to a patient within seven days of the initial blood draw. Its subsidiaries include Kwalata Trading Limited, Hemostemix Ltd., and PreCerv Inc.


TSXV:HEM - Post by User

Bullboard Posts
Comment by dt_coreon Jul 23, 2012 2:06pm
176 Views
Post# 20143125

RE: RE: RE: Q2 CC

RE: RE: RE: Q2 CC

It comes down to if you think 2013/2014's profits will justify the investment in R&D, Marketing etc. At the end of the day you have to ask yourself what shape the company would be in today if they didn't make the investment. Having said that there have been some unwise choices (Earthworks anyone!?), but not all R&D projects will be successful, and that goes for any company (that's why it's called R&D rather than product creation). If HEM were to cut spending, the business would never achieve scale and the company would achieve profits only until the business eroded into obscurity. So, as a going concern the business needs to spend on these areas. Whether they could have done so more efficiently though is another issue.

 

Net net, if in 2013/2014 revenue growth occurs from this years product launch + new distribution agreements and the business has sufficient opperating leverage you suddenly get a meaningful business with future potential. Cut now and yes you'll get a near term earnings lift (and a substantial one), but the company would then have maybe a 3-5 year life tops and investors will sell off the stock to nothingness. As SK accuratly said, this business is driven from innovation and if they don't keep up then there will be no business left. Fortunately Outback Max is really looking like a winner to those I've spoken to who know far better than I.

Bullboard Posts